Cargando…
Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:27...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144873/ https://www.ncbi.nlm.nih.gov/pubmed/37109444 http://dx.doi.org/10.3390/life13040915 |
_version_ | 1785034198350823424 |
---|---|
author | López-Vilella, Raquel Guerrero Cervera, Borja Donoso Trenado, Víctor Sánchez-Lázaro, Ignacio Martínez Dolz, Luis Almenar Bonet, Luis |
author_facet | López-Vilella, Raquel Guerrero Cervera, Borja Donoso Trenado, Víctor Sánchez-Lázaro, Ignacio Martínez Dolz, Luis Almenar Bonet, Luis |
author_sort | López-Vilella, Raquel |
collection | PubMed |
description | Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:272) and treated (n:540) patients were compared. The six-month prevalence of a combined event (readmission for HF, all-cause death, and emergency department visit for decompensation) was analysed. Three grades of renal dysfunction (KDIGO) were compared, Group 1 (grades 1 and 2), Group 2 (grades 3a and 3b), and Group 3 (grades 4 and 5). Results: There were differences in sex distribution (untreated group: males 39.7% vs. treated group: males 51.9%; p < 0.001). Sex-adjusted combined event analysis showed a greater benefit in Group 1 (OR: 0.31, 95% CI:0.19–0.5; p < 0.001) and Group 2 (OR: 0.23, 95% CI:0.14–0.38; p < 0.001), but not in Group 3 (OR: 0.51, 95% CI:0.17–0.55; p: 0.237). Conclusions: The administration of FCM in patients with AHF and ID reduces the combined event analysed. The benefit is greater when renal dysfunction is present, except in very advanced degrees where no significant benefit is obtained. |
format | Online Article Text |
id | pubmed-10144873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101448732023-04-29 Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? López-Vilella, Raquel Guerrero Cervera, Borja Donoso Trenado, Víctor Sánchez-Lázaro, Ignacio Martínez Dolz, Luis Almenar Bonet, Luis Life (Basel) Article Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:272) and treated (n:540) patients were compared. The six-month prevalence of a combined event (readmission for HF, all-cause death, and emergency department visit for decompensation) was analysed. Three grades of renal dysfunction (KDIGO) were compared, Group 1 (grades 1 and 2), Group 2 (grades 3a and 3b), and Group 3 (grades 4 and 5). Results: There were differences in sex distribution (untreated group: males 39.7% vs. treated group: males 51.9%; p < 0.001). Sex-adjusted combined event analysis showed a greater benefit in Group 1 (OR: 0.31, 95% CI:0.19–0.5; p < 0.001) and Group 2 (OR: 0.23, 95% CI:0.14–0.38; p < 0.001), but not in Group 3 (OR: 0.51, 95% CI:0.17–0.55; p: 0.237). Conclusions: The administration of FCM in patients with AHF and ID reduces the combined event analysed. The benefit is greater when renal dysfunction is present, except in very advanced degrees where no significant benefit is obtained. MDPI 2023-03-31 /pmc/articles/PMC10144873/ /pubmed/37109444 http://dx.doi.org/10.3390/life13040915 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article López-Vilella, Raquel Guerrero Cervera, Borja Donoso Trenado, Víctor Sánchez-Lázaro, Ignacio Martínez Dolz, Luis Almenar Bonet, Luis Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title | Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title_full | Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title_fullStr | Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title_full_unstemmed | Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title_short | Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? |
title_sort | is the benefit of treating iron deficiency greater in acute heart failure with renal dysfunction? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144873/ https://www.ncbi.nlm.nih.gov/pubmed/37109444 http://dx.doi.org/10.3390/life13040915 |
work_keys_str_mv | AT lopezvilellaraquel isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction AT guerrerocerveraborja isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction AT donosotrenadovictor isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction AT sanchezlazaroignacio isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction AT martinezdolzluis isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction AT almenarbonetluis isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction |